蔗糖铁与右旋糖酐铁治疗维持性血液透析并肾性贫血的临床疗效比较研究

发布时间：2018-10-22 15:23

【摘要】：目的比较蔗糖铁与右旋糖酐铁治疗维持性血液透析(MHD)并肾性贫血的临床疗效。方法选取北京市仁和医院2015年6月—2016年6月收治的MHD并肾性贫血患者64例,根据治疗药物不同分为对照组(n=32)和观察组(n=32)。对照组患者给予右旋糖酐铁治疗,观察组患者给予蔗糖铁治疗,均持续治疗5周。比较两组患者的临床疗效,治疗前后血液学指标[网织红细胞计数、红细胞计数、红细胞比容(Hct)、血红蛋白(Hb)]及铁相关指标[总铁结合力、血清铁、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)及促红细胞生成素(EPO)剂量],并比较两组患者不良反应发生情况。结果观察组患者临床疗效优于对照组(P0.05)。治疗前及治疗后,两组患者网织红细胞计数、红细胞计数、Hct、Hb比较,差异无统计学意义(P0.05);治疗后,两组患者网织红细胞计数少于治疗前,红细胞计数、Hct、Hb高于治疗前(P0.05)。治疗前及治疗后,两组患者总铁结合力、血清铁、SF、TSAT及EPO剂量比较,差异无统计学意义(P0.05);治疗后,两组患者总铁结合力低于治疗前,血清铁、SF、TAST高于治疗前(P0.05),但两组患者治疗前后EPO剂量比较,差异无统计学意义(P0.05)。两组患者均未出现严重不良反应。结论蔗糖铁与右旋糖酐铁均可有效改善MHD并肾性贫血患者铁及血液指标,而蔗糖铁治疗MHD并肾性贫血的临床疗效优于旋糖酐铁。
[Abstract]:Objective to compare the clinical efficacy of iron sucrose and iron dextran in the treatment of maintenance hemodialysis (MHD) with renal anemia. Methods Sixty-four patients with MHD complicated with renal anemia from June 2015 to June 2016 in Renhe Hospital of Beijing were divided into two groups: control group (n = 32) and observation group (n = 32). The patients in the control group were treated with iron dextran and the patients in the observation group were treated with iron sucrose for 5 weeks. The clinical efficacy, hematologic indexes [reticulocyte count, erythrocyte specific volume (Hct), hemoglobin (Hb)] and iron-related indexes [total iron binding force, serum iron, serum iron] before and after treatment were compared between the two groups. Serum ferritin (SF), transferrin saturation (TSAT) and erythropoietin (EPO) dosages were compared between the two groups. Results the clinical effect of the observation group was better than that of the control group (P0.05). Before and after treatment, there was no significant difference in reticulocyte count and Hct,Hb between the two groups (P0.05); after treatment, the reticulocyte count in the two groups was less than that before treatment, and the Hct,Hb was higher than that before treatment (P0.05). Before and after treatment, there was no significant difference in the total iron binding ability, serum iron, SF,TSAT and EPO doses between the two groups (P0.05), and the total iron binding ability of the two groups was lower than that before treatment. Serum iron, SF,TAST was higher than before treatment (P0.05), but the two groups of patients before and after treatment EPO dose comparison, there was no significant difference (P0.05). There were no serious adverse reactions in both groups. Conclusion both iron sucrose and iron dextran can effectively improve iron and blood indexes in patients with MHD complicated with renal anemia. The clinical efficacy of iron sucrose in the treatment of MHD with renal anemia is better than that of iron.
【作者单位】：北京市仁和医院重症医学科;
【分类号】：R692.5;R556

【参考文献】